Last modification : Wednesday, November 16, 2022
Prof. Dr. Karen Vanhoorelbeke of KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium is hiring one of the 8 PhD students in the MSCA TOLERATE project. Prof Karen Vanhoorelbeke has an international recognised expertise is unraveling the pathophysiology if the autoimmune disease immune-mediated thrombotic thrombocytopenic purpura (iTTP), in animal models for this disease and in developing novel diagnostic assays and therapies for iTTP. (https: // thrombosis.kuleuven-kulak.be/van-hoorelbeke-lab/). Prof Vanhoorelbeke is the coordinator of TOLERATE. TOLERATE training network aims at training Doctoral Candidates' (DCs) (PhD students) to acquire the skills to develop different innovative strategies to treat autoimmune diseases, to identify the most promising strategies or a combination of strategies, to setup clinical trials and to develop a roadmap to bring a novel therapeutic agent to the market. This all will be done in a highly interdisciplinary and intersectoral environment. Interdisciplinarity allows to introduce innovative tolerogenic therapies developed for cancer, Chimer Antigen Receptor (CAR)-T cell therapies, into the world of autoimmune disease and to apply nanotechnology and protein-engineered tolerogenic vaccines to re-establish immune tolerance in autoimmune disease. Both the presence of academia and industry provides a platform for in-depth preclinical studies and a realistic possibility for future commercialization of the novel therapies. Clinicians in the consortium with expertise in setting-up and running clinical trials for novel drugs assure that developed novel therapies in TOLERATE will find their way to the clinic in the future. Developing novel therapies for autoimmune diseases goes close together with a thorough knowledge on the long-term consequences of living with an autoimmune disease. Since many autoimmune diseases are rare diseases, setting up international uniform databases and biobanks is crucial to understand the long-term pathophysiology of the disease and to guarantee optimal use of (novel) therapies. TOLERATE will train 8 DCs who will hence have the expertise and skills to work in and setup interdisciplinary and intersectoral projects. The ground-breaking training programme will provide the DCs with a unique clinical training. Additional training in ethical, regulatory and legal aspects together with a training in innovation management of therapeutics and diagnostics for autoimmune diseases will prepare the DCs for the European job market.
Subject area Genetic engineering, UniCAR-T cell therapy, mouse models, autoimmune disease immune-mediated thrombotic thrombocytopenic purpura.
Project-specific selection criteria DC2 will develop the innovative UniCAR-T cell therapy to treat the autoimmune disease using immune-mediated thrombotic thrombocytopenic purpura (iTTP) as a model disease. UniCAR-T cells will be generated via genetic engineering. The UniCAR-T cell therapy will be tested both in vitro and in vivo in a mouse model of iTTP.Profile
The DC will be selected through a 2-step recruitment process.
1. Candidates should submit their application in English which should include:
More details of the procedure and details of needed documents are available on the website https: // www. tolerate-horizon.eu and on the downloadable PDF .
The closing date for applications is 15/12/2022
Application documents should be sent by email to Prof. dr. Karen Vanhoorelbeke: firstname.lastname@example.org
Candidates will be evaluated by the recruiting institution on the basis of the received documents.
2. The best 2 candidates will be invited for a face to face interview in the period 15-31 January 2023.
A list of the top candidates will be prepared and notified to the applicants.
The top candidates will be asked to provide a written acceptance of the studentship; then the following ranked candidates will be requested to confirm. If a successful candidate declines the offer, the studentship will be offered to the next ranked candidate.
For more information please also contact Prof. dr. Karen Vanhoorelbeke, tel.: +32 56 24 60 61, mail: email@example.com.
KU Leuven seeks to foster an environment where all talents can flourish, regardless of gender, age, cultural background, nationality or impairments. If you have any questions relating to accessibility or support, please contact us at diversiteit.HR@kuleuven.be.